BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:alvelestat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of alvelestat\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02669251-1541@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:alvelestat: Phase 1/2 readout est. (NCT02669251)
DESCRIPTION:alvelestat\, phase 1/2.\nStudy: Alvelestat (MPH966)\, an Oral N
 eutrophil Elastase Inhibitor\, in Bronchiolitis Obliterans Syndrome After 
 Allogeneic Hematopoietic Stem Cell Transplantation\nEstimated primary comp
 letion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/alvelestat#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT02669251
URL:https://assetmemo.bio/drug/alvelestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
